From HIV to COVID-19, Molecular mechanisms of pathogens' trade-off and persistence in the community, potential targets for new drug development.
COVID-19
Invasion–persistence
OMICRON
Trade-off
Virulence–transmissibility
Journal
Bulletin of the National Research Centre
ISSN: 2522-8307
Titre abrégé: Bull Natl Res Cent
Pays: Germany
ID NLM: 101755158
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
05
2022
accepted:
22
06
2022
entrez:
12
7
2022
pubmed:
13
7
2022
medline:
13
7
2022
Statut:
ppublish
Résumé
On the staggering emergence of the Omicron variant, numerous questions arose about the evolution of virulence and transmissibility in microbes. The trade-off hypothesis has long speculated the exchange of virulence for the sake of superior transmissibility in a wide array of pathogens. While this certainly applies to the case of the Omicron variant, along with influenza virus, various reports have been allocated for an array of pathogens such as human immunodeficiency virus (HIV), malaria, hepatitis B virus (HBV) and tuberculosis (TB). The latter abide to another form of trade-off, the invasion-persistence trade-off. In this study, we aim to explore the molecular mechanisms and mutations of different obligate intracellular pathogens that attenuated their more morbid characters, virulence in acute infections and invasion in chronic infections. Recognizing the mutations that attenuate the most morbid characters of pathogens such as virulence or persistence can help in tailoring new therapies for such pathogens. Targeting macrophage tropism of HIV by carbohydrate-binding agents, or targeting the TMPRSS2 receptors to prevent pulmonary infiltrates of COVID-19 is an example of how important is to recognize such genetic mechanisms.
Sections du résumé
Background
UNASSIGNED
On the staggering emergence of the Omicron variant, numerous questions arose about the evolution of virulence and transmissibility in microbes.
Main body of the abstract
UNASSIGNED
The trade-off hypothesis has long speculated the exchange of virulence for the sake of superior transmissibility in a wide array of pathogens. While this certainly applies to the case of the Omicron variant, along with influenza virus, various reports have been allocated for an array of pathogens such as human immunodeficiency virus (HIV), malaria, hepatitis B virus (HBV) and tuberculosis (TB). The latter abide to another form of trade-off, the invasion-persistence trade-off. In this study, we aim to explore the molecular mechanisms and mutations of different obligate intracellular pathogens that attenuated their more morbid characters, virulence in acute infections and invasion in chronic infections.
Short conclusion
UNASSIGNED
Recognizing the mutations that attenuate the most morbid characters of pathogens such as virulence or persistence can help in tailoring new therapies for such pathogens. Targeting macrophage tropism of HIV by carbohydrate-binding agents, or targeting the TMPRSS2 receptors to prevent pulmonary infiltrates of COVID-19 is an example of how important is to recognize such genetic mechanisms.
Identifiants
pubmed: 35818410
doi: 10.1186/s42269-022-00879-w
pii: 879
pmc: PMC9258762
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
194Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Nat Commun. 2021 Jan 22;12(1):530
pubmed: 33483501
Nature. 2022 May;605(7909):340-348
pubmed: 35344983
Nat Rev Microbiol. 2022 Apr 27;:
pubmed: 35478222
Future Med Chem. 2020 Mar;12(5):457-467
pubmed: 32053005
Elife. 2020 Jun 22;9:
pubmed: 32568069
Curr Opin Virol. 2021 Oct;50:110-118
pubmed: 34454351
Curr Opin Virol. 2014 Oct;8:79-84
pubmed: 25087040
J Evol Biol. 2009 Feb;22(2):245-59
pubmed: 19196383
BMC Infect Dis. 2018 Jun 1;18(1):251
pubmed: 29859062
Science. 2007 Feb 2;315(5812):655-9
pubmed: 17272724
Proc Biol Sci. 2020 May 27;287(1927):20200496
pubmed: 32396798
Front Immunol. 2022 Mar 14;13:827760
pubmed: 35359920
J Med Virol. 2022 May;94(5):2019-2025
pubmed: 34997962
J Genet Genomics. 2021 Dec;48(12):1111-1121
pubmed: 34954396
Sci Rep. 2021 Jan 29;11(1):2628
pubmed: 33514768
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
Lancet Respir Med. 2021 Feb;9(2):135-136
pubmed: 33245861
J Med Virol. 2022 Apr;94(4):1641-1649
pubmed: 34914115
Gastroenterology. 2009 Nov;137(5):1593-608.e1-2
pubmed: 19737565
Tuberculosis (Edinb). 2019 Jul;117:7-17
pubmed: 31378272
J Family Med Prim Care. 2021 Mar;10(3):1117-1123
pubmed: 34041138
World J Hepatol. 2015 Mar 27;7(3):583-92
pubmed: 25848482
Viruses. 2022 Jan 17;14(1):
pubmed: 35062369
Gastroenterology. 2005 Jul;129(1):234-45
pubmed: 16012950
Adv Funct Mater. 2014 Sep 10;24(34):5340-5347
pubmed: 25419208
Viruses. 2019 Aug 24;11(9):
pubmed: 31450544
AIDS Res Hum Retroviruses. 2018 Sep;34(9):739-759
pubmed: 30056745
J Virol. 2015 Nov;89(22):11294-311
pubmed: 26339058
Int J Biol Macromol. 2022 Apr 15;204:161-168
pubmed: 35074332
Infect Drug Resist. 2021 Jun 28;14:2419-2427
pubmed: 34234472
Front Cell Infect Microbiol. 2019 Jul 30;9:272
pubmed: 31428590
EMBO J. 2021 Aug 16;40(16):e107821
pubmed: 34159616
Front Immunol. 2017 Feb 15;8:84
pubmed: 28261197
Cell Death Dis. 2021 Jan 22;12(1):119
pubmed: 33483474
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Emerg Microbes Infect. 2022 Dec;11(1):277-283
pubmed: 34951565
Int J Biol Sci. 2022 Jan 1;18(2):889-900
pubmed: 35002532
Front Microbiol. 2022 Apr 27;13:862270
pubmed: 35572626
Front Microbiol. 2021 May 13;12:667561
pubmed: 34054775
Biol Rev Camb Philos Soc. 2004 Nov;79(4):849-69
pubmed: 15682873
J Cell Biochem. 2013 Jan;114(1):1-6
pubmed: 22833514
Nat Ecol Evol. 2022 Jan;6(1):51-62
pubmed: 34949816
J Evol Biol. 2021 Aug;34(8):1256-1265
pubmed: 34101932
Elife. 2021 Sep 21;10:
pubmed: 34544548
J Med Virol. 2022 May;94(5):1761-1765
pubmed: 35014038
Molecules. 2018 Nov 08;23(11):
pubmed: 30413024
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
PLoS Pathog. 2014 Oct 23;10(10):e1004387
pubmed: 25340792
Lancet Infect Dis. 2022 Jan;22(1):16
pubmed: 34953540
BMC Infect Dis. 2019 May 22;19(1):449
pubmed: 31113377
Front Microbiol. 2021 Apr 07;12:646447
pubmed: 33897659
J Plant Res. 2012 Mar;125(2):291-300
pubmed: 21638005
PLoS Pathog. 2010 Sep 30;6(9):e1001123
pubmed: 20941398
Am Nat. 2009 Apr;173(4):446-55
pubmed: 19231966
Influenza Other Respir Viruses. 2008 Sep;2(5):147-54
pubmed: 19453419
Front Immunol. 2020 Mar 04;11:401
pubmed: 32194573
Front Cell Infect Microbiol. 2022 Feb 04;12:827717
pubmed: 35186800